RIO DE JANEIRO, BRAZIL - The Industrial Complex of Biotechnology in Health of the Oswaldo Cruz Foundation (Cibs/Fiocruz), now under construction, will increase fivefold the production capacity of the Institute of Technology in Immunobiology (Bio-Manguinhos/Fiocruz).
Vaccines against meningitis, hepatitis, and triple bacterial infection, which are currently imported, will be produced at its base in the Industrial District of Santa Cruz, in the western zone of Rio de Janeiro. In addition to production, specific vaccines for schistosomiasis and leprosy will also be added.
The New Final Processing Center (NCPFI) will cover a total area of 580,000 m² and . . .